Data from the KEYNOTE-158 study, presented at the Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer, showed durable responses in heavily pretreated patients with vulvar squamous cell carcinoma regardless of their PD-L1 status.
The combination of apatinib and pegylated liposomal doxorubicin improved the progression-free survival for patients with platinum-resistant or refractory ovarian cancer in comparison to doxorubicin alone, according to data from the phase 2 APPROVE trial.
Patients with advanced or recurrent endometrioid endometrial cancer had promising clinical outcomes following treatment with the combination of enzalutamide and carboplatin plus paclitaxel in the phase 2 ENPAC clinical trial.
After long-term follow-up, olaparib maintenance therapy demonstrated progression-free survival benefit in almost half of the patients with ovarian cancer compared with 21% for those who received placebo, including consistent benefit in high- and low-risk patients.
Niraparib administered as maintenance therapy showed clinical benefit lasting beyond first progression in patients with platinum-sensitive recurrent ovarian cancer with or without germline BRCA mutations, according to the final results of the ENGOT-OV16/NOVA study.
At the Society of Gynecological Oncology Virtual Annual Meeting on Women’s Cancer data from the phase II OVARIO study continued to show the progression free survival benefit for heavily pretreated patients with advanced ovarian cancer.